Pricing Log in Create free account

Immunocore Holdings PLC Sponsored ADR (IMCR) vs Ultragenyx Pharmaceutical Inc. (RARE)

Immunocore Holdings PLC Sponsored ADR and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Immunocore Holdings PLC Sponsored ADR and Ultragenyx Pharmaceutical Inc. are of similar size ($1.5B and $1.5B). Immunocore Holdings PLC Sponsored ADR grew revenue faster over the last twelve months: 21.0% against 17.5%. Immunocore Holdings PLC Sponsored ADR has the higher net margin (−4.20% vs −81.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Immunocore Holdings PLC Sponsored ADR leads on 11 and Ultragenyx Pharmaceutical Inc. on 5.

Valuation

Metric IMCR RARE Biotechnology median
P/E n/m n/m 8.50
P/S 3.48 2.07 9.71
P/B 3.57 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 2.46 1.66 9.21
Earnings yield (1.22%) (40.17%) (33.15%)
Free cash flow yield (2.75%) (33.34%) (25.50%)

Profitability

Metric IMCR RARE Biotechnology median
Gross margin 98.90% 83.12% 65.16%
Operating margin (5.24%) (73.64%) 0.00%
Net margin (4.20%) (81.73%) 0.00%
Free cash flow margin (9.55%) (68.90%) 0.00%
Return on equity (4.47%) 838.86% (56.36%)
Return on assets (1.64%) (45.60%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMCR RARE Biotechnology median
Revenue growth (TTM) 20.95% 17.51% 6.02%
EPS growth (last fiscal year) 30.39% 7.31% 30.26%
Revenue growth, 5-year CAGR 59.57% 19.95% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMCR RARE Biotechnology median
Debt to equity 0.94 0.00 0.00
Current ratio 4.47 1.73 4.72
Net debt to EBITDA 11.19 1.35 0.96

Dividend

Metric IMCR RARE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IMCR RARE Biotechnology median
Market cap 1.52b 1.50b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack